HILDEN, Germany, and TOKYO--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that the Japanese Pharmaceuticals and Medical Device Agency (PMDA) has approved the ...
It can assess patients’ suitability for Amgen’s colorectal cancer drug, Vectibix. Canadian regulatory authorities approved DxS’ TheraScreen K-RAS Mutation Kit for use as a diagnostic for anti-EGFR ...
- Lung cancer causes more than 1.7 million deaths worldwide each year, with NSCLC accounting for about 85 percent of all cases[1] - The cobas EGFR Mutation Test v2 is FDA approved as a companion ...
Guardant Health blood test identifies patients with EGFR exon 20 insertion mutations who may benefit from targeted treatment with RYBREVANT™ after progressing on or after platinum-based chemotherapy ...
Antibody-drug conjugates (ADCs) have emerged as the primary solution for patients who have progressed on EGFR inhibitors and ...
EML4-ALK rearrangement detection in malignant pleural effusions from patients with advanced non-small cell lung cancer: Feasibility and predictive value. This is an ASCO Meeting Abstract from the 2015 ...
It has been reported that EGFR mutations in lung carcinomas make the disease more responsive to treatment with tyrosine kinase inhibitors. We decided to evaluate the prevalence of EGFR mutations in a ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Foundation Medicine, Inc. a pioneer in molecular profiling for cancer, today announced it has received approval from the U.S. Food and Drug Administration (FDA) for ...
CNS metastases in EGFR-mutant NSCLC are prevalent and worsen prognosis, especially with acquired progression during treatment. Amivantamab plus lazertinib shows promising CNS activity, but current ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results